Insulin resistance and lipid disorders

Bibliography

• Farag A, Karam J, Nicasio J, McFarlane SI:Prevention of Type 2 diabetes: an update.Curr. Diab. Rep. 7, 200–207 (2007)
   Google Scholar
• Pi-Sunyer FX: How effective are lifestylechanges in the prevention of Type 2 diabetesmellitus? Nutr. Rev. 65, 101–110 (2007)
   Google Scholar
• Reaven GM: Pathophysiology of insulinresistance in human disease. Physiol. Rev.75, 473–486 (1995)
   Google Scholar
• Grundy SM: Small LDL, atherogenicdyslipidemia and the metabolic syndrome.Circulation 95, 1–4 (1997)
   Google Scholar
• Ginsberg HN, Zhang YL, Hernandez-Ono A:Metabolic syndrome: focus on dyslipidemia.Obesity 14(1), 41S–49S (2006)
   Google Scholar
• D'Agostino RB Jr, Hamman RF, Karter AJ,Mykkanen L, Wagenknecht LE, Haffner SM;Insulin Resistance Atherosclerosis StudyInvestigators: Cardiovascular disease riskfactors predict the development of Type 2diabetes: the Insulin Resistance AtherosclerosisStudy. Diabetes Care 27(9), 2234–2240 (2004).
   Google Scholar
• Demonstrates that individuals with multiplecardiovascular disease risk factors are atincreased risk of Type 2 diabetes (T2DM),which is only partially mediated by insulinresistance or central adiposity.
   Google Scholar
• Baldeweg SE, Golay A, Natali A, Balkau B,Del Prato S, Coppack SW: Insulin resistance,lipid and fatty acid concentrations in 867healthy Europeans: European Group for theStudy of Insulin Resistance (EGIR). Eur.J. Clin. Invest. 30, 45–52 (2000)
   Google Scholar
• Festa A, Williams K, Hanley AJ et al.: Nuclearmagnetic resonance lipoprotein abnormalitiesin prediabetic subjects in the Insulin ResistanceAtherosclerosis Study. Circulation 111(25),3465–3472 (2005)
   Google Scholar
• Chen YD, Swami S, Skowronski R,Coulston A, Reaven GM: Differences inpostprandial lipemia between patients withnormal glucose tolerance and non-insulindependentdiabetes mellitus. J. Clin. Endocrinol.Metab. 76, 172–177 (1993)
   Google Scholar
• Lewis GF, O'Meara NM, Soltys PA et al.:Fasting hypertriglyceridemia in noninsulindependentdiabetes mellitus is an importantpredictor of postprandial lipid and lipoproteinabnormalities. J. Clin. Endocrinol. Metab. 72,934–944 (1991)
   Google Scholar
• Syvänne M, Hilden H, Taskinen MR:Abnormal metabolism of postprandiallipoproteins in patients with non-insulindependentdiabetes mellitus is not related tocoronary artery disease. J. Lipid Res. 35, 15–26(1994)
   Google Scholar
• Cavallero E, Dachet C, Neufcour D,Wirquin E, Mathe D, Jacotot B: Postprandialamplifi cation of lipoprotein abnormalities incontrolled Type II diabetic subjects:relationship to postprandial lipemia andC-peptide: glucagon levels. Metabolism 43,270–278 (1994)
   Google Scholar
• Rivellese AA, De Natale C, Di Marino Let al.: Exogenous and endogenouspostprandial lipid abnormalities in Type 2diabetic patients with optimal blood glucosecontrol and optimal fasting triglyceride levels.J. Clin. Endocrinol. Metab. 89(5), 2153–2159(2004)
   Google Scholar
• Annuzzi G, De Natale C, Iovine C et al.:Insulin resistance is independently associatedwith postprandial alterations of triglyceriderichlipoproteins in Type 2 diabetes mellitus.Arterioscler. Thromb. Vasc. Biol. 24,2397–2402 (2004)
   Google Scholar
• Mero N, Malmström R, Steiner G,Taskinen MR, Syvänne M: Postprandialmetabolism of apolipoprotein B-48- andB-100-containing particles in Type 2 diabetesmellitus: relations to angiographically verifi edseverity of coronary artery disease.Atherosclerosis 150, 167–177 (2000)
   Google Scholar
• Ford ES, Giles WH, Dietz WH: Prevalence ofthe metabolic syndrome among US adults:fi ndings from the third National Health andNutrition Examination Survey. JAMA 287,356–359 (2002)
   Google Scholar
• Miccoli R, Bianchi C, Odoguardi L et al.:Prevalence of the metabolic syndrome amongItalian adults according to ATP III defi nition.Nutr. Metab. Cardiovasc. Dis. 15(15), 250–254(2005)
   Google Scholar
• Wyszynski DF, Waterworth DM, Barter PJet al.: Relation between atherogenicdyslipidemia and the Adult TreatmentProgram-III defi nition of metabolic syndrome(Genetic Epidemiology of Metabolic SyndromeProject). Am. J. Cardiol. 95(2), 194–198(2005)
   Google Scholar
• Rivellese AA, Patti L, Kaufman D et al.:Lipoprotein particle distribution and size,insulin resistance and metabolic syndrome inAlaska Eskimos: the GOCADAN Study.Atherosclerosis (2008) (Epub ahead of print)
   Google Scholar
• Ghiadoni L, Penno G, Giannarelli C et al.:Metabolic syndrome and vascular alterations innormotensive subjects at risk of diabetesmellitus. Hypertension 51(2), 440–445 (2008)
   Google Scholar
• Ginsberg HN, Zhang YL, Hernandez-Ono A:Regulation of plasma triglycerides in insulinresistance and diabetes. Arch. Med. Res. 36,232–240 (2005)
   Google Scholar
• Krauss RM: Triglycerides andatherogenic lipoproteins: rationale for lipidmanagement. Am. J. Med. 105(1A), 58S–62S(1998)
   Google Scholar
• Ginsberg HN: Insulin resistance andcardiovascular disease. J. Clin. Invest. 106,453–458 (2000)
   Google Scholar
• Berg CE, Lavan BE, Rondinone CM:Rapamycin partially prevents insulin resistanceinduced by chronic insulin treatment. Biochem.Biophys. Res. Commun. 293(3), 1021–1027(2002)
   Google Scholar
• Fisher EA, Ginsberg HN: Complexityin the secretory pathway: the assembly andsecretion of apolipoprotein B-containinglipoproteins. J. Biol. Chem. 277, 17377–17380(2002)
   Google Scholar
• Gusarova V, Caplan AJ, Brodsky JL, Fisher EA:Apoprotein B degradation is promoted by themolecular chaperones Hsp90 and Hsp70.J. Biol. Chem. 276, 24891–24900 (2001)
   Google Scholar
• Sparks JD, Sparks CE: Insulin regulation oftriacylglycerol-rich lipoprotein synthesis andsecretion. Biochim. Biophys. Acta. 1215, 9–32(1994)
   Google Scholar
• Au WS, Kung HF, Lin MC: Regulation ofmicrosomal triglyceride transfer protein gene byinsulin in HepG2 cells: roles of MAPKerk andMAPKp38. Diabetes 52, 1073–1080 (2003)
   Google Scholar
• Phung TL, Roncone A, Jensen KL, Sparks CE,Sparks JD: Phosphoinositide 3-kinase activity isnecessary for insulin-dependent inhibition ofapolipoprotein B secretion by rat hepatocytesand localizes to the endoplasmic reticulum.J. Biol. Chem. 272, 30693–30702 (1997)
   Google Scholar
• Berti L, Mosthaf L, Kroder G et al.: Glucoseinducedtranslocation of protein kinase Cisoforms in rat-1 fi broblasts is paralleled byinhibition of the insulinreceptor tyrosine kinase. J. Biol. Chem. 269,3381–3386 (1994)
   Google Scholar
• Lewis GF, Uffelman KD, Szeto LW, Steiner G:Effects of acute hyperinsulinemia on VLDLtriglyceride and VLDL ApoB production innormal weight and obese individuals. Diabetes42, 833–842 (1993)
   Google Scholar
• Adiels M, Westerbacka J, Soro-Paavonen Aet al.: Acute suppression of VLDL1 secretionrate by insulin is associated with hepatic fatcontent and insulin resistance. Diabetologia50(11), 2356–2365 (2007).
   Google Scholar
• Demonstates that elevated plasma glucosecan further increase hepatic fat contentthrough multiple pathways, resulting inoverproduction of VLDL1 particles andleading to the characteristic dyslipidemiaassociated with T2DM.
   Google Scholar
• Adiels M, Olofsson SO, Taskinen MR,Borén J: Overproduction of very low-densitylipoproteins is the hallmark of the dyslipidemiain the metabolic syndrome. Arterioscler.Thromb. Vasc. Biol. 28, 1225–1236 (2008)
   Google Scholar
• Riches FM, Watts GF, Naoumova RP et al.:Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studiedwith a stable isotope technique in men withvisceral obesity. Int. J. Obes. Relat. Metab.Disord. 22, 414–423 (1998)
   Google Scholar
• Craig WY, Nutik R, Cooper AD: Regulation ofapoprotein synthesis and secretion in thehuman hepatoma Hep G2. The effect ofexogenous lipoprotein. J. Biol. Chem. 263,13880–13890 (1988)
   Google Scholar
• Cohn JS, Wagner DA, Cohn SD, Millar JS,Schaefer EJ: Measurement of very low densityand low density lipoprotein apolipoprotein(Apo) B-100 and high density lipoproteinApoA-I production in human subjects usingdeuterated leucine. Effect of fasting andfeeding. J. Clin. Invest. 85, 804–811 (1990)
   Google Scholar
• Diraison F, Moulin P, Beylot M: Contributionof hepatic de novo lipogenesis andreesterifi cation of plasma nonesterifi ed fattyacids to plasma triglyceride synthesis duringnon-alcoholic fatty liver disease. DiabetesMetab. 29, 478–485 (2003)
   Google Scholar
• Schwarz JM, Linfoot P, Dare D,Aghajanian K: Hepatic de novo lipogenesis innormoinsulinemic and hyperinsulinemicsubjects consuming high-fat, low-carbohydrateand low-fat, high-carbohydrate isoenergeticdiets. Am. J. Clin Nutr. 77, 43–50 (2003)
   Google Scholar
• Horton JD, Goldstein JL, Brown MS:SREBPs: activators of the complete program ofcholesterol and fatty acid synthesis in the liver.J. Clin. Invest. 109, 1125–1131 (2002)
   Google Scholar
• Richardson MC, Cameron IT, Simonis CDet al.: Insulin and human chorionicgonadotropin cause a shift in the balance ofsterol regulatory element-binding protein(SREBP) isoforms toward the SREBP-1cisoform in cultures of human granulosa cells.J. Clin. Endocrinol. Metab. 90(6), 3738–3746(2005)
   Google Scholar
• Shimomura I, Matsuda M, Hammer RE,Bashmakov Y, Brown MS, Goldstein JL:Decreased IRS-2 and increased SREBP-1c leadto mixed insulin resistance and sensitivity inlivers of lipodystrophic and ob/ob mice. Mol.Cell. 6(1), 77–86 (2000)
   Google Scholar
• Brown MS, Goldstein JL: Selective versus totalinsulin resistance: a pathogenic paradox. Cell.Metab. 7, 95–96 (2008)
   Google Scholar
• Cha JY, Repa JJ: The liver X receptor (LXR)and hepatic lipogenesis. The carbohydrateresponseelement-binding protein is a targetgene of LXR. J. Biol. Chem. 282, 743–751(2007)
   Google Scholar
• Haidari M, Leung N, Mahbub F et al.: Fastingand postprandial overproduction of intestinallyderived lipoproteins in an animal model ofinsulin resistance. Evidence that chronicfructose feeding in the hamster is accompaniedby enhanced intestinal de novo lipogenesis andApoB48-containing lipoproteinoverproduction. J. Biol. Chem. 277, 31646–31655 (2002)
   Google Scholar
• Lewis GF: Intestinal lipoproteinoverproduction, a newly recognized componentof insulin resistance, is ameliorated by theinsulin sensitizer rosiglitazone: studies in thefructose-fed Syrian golden hamster.Endocrinology 146, 247–255 (2005)
   Google Scholar
• Cohn JS, Patterson BW, Uffelman KD,Davignon J, Steiner G: Rate of production ofplasma and very-low-density lipoprotein(VLDL) apolipoprotein C-III is strongly relatedto the concentration and level of production ofVLDL triglyceride in male subjects withdifferent body weights and levels of insulinsensitivity. J. Clin. Endocrinol. Metab. 89,3949–3955 (2004)
   Google Scholar
• Duez H, Lamarche B, Uffelman KD, Valero R,Cohn JS, Lewis GF: Hyperinsulinemia isassociated with increased production rate ofintestinal apolipoprotein B-48-containinglipoproteins in humans. Arterioscler. Thromb.Vasc. Biol. 26, 1357–1363 (2006)
   Google Scholar
• Lewis GF, Rader DJ: New insights into theregulation of HDL metabolism and reversecholesterol transport. Circ. Res. 96, 1221–1232(2005)
   Google Scholar
• Le Goff W, Guerin M, Chapman MJ:Pharmacological modulation of cholesteryl estertransfer protein, a new therapeutic target inatherogenic dyslipidemia. Pharmacol. Ther.101, 17–38 (2004)
   Google Scholar
• Borggreve SE, De Vries R, Dullaart RP:Alterations in high-density lipoproteinmetabolism and reverse cholesterol transportin insulin resistance and Type 2 diabetesmellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transferproteins. Eur. J. Clin. Invest. 33, 1051–1069(2003)
   Google Scholar
• Biddinger SB, Hernandez-Ono A, Rask-Madsen C et al.: Hepatic insulin resistance issuffi cient to produce dyslipidemia andsusceptibility to atherosclerosis. Cell. Metab.7, 125–134 (2008).
   Google Scholar
• First study demonstrating that micewith T2DM manifest selective hepaticinsulin resistance: insulin fails tosuppress gluconeogenesis but continuesto activate lipogenesis, producing thedeadly combination of hyperglycemiaand hypertriglyceridemia.
   Google Scholar
• Soedamah-Muthu SS, Chang YF, Otvos J,Evans RW, Orchard TJ: Lipoproteinsubclass measurements by nuclear magneticresonance spectroscopy improve theprediction of coronary artery disease inType 1 diabetes: a prospective report fromthe Pittsburgh Epidemiology of DiabetesComplications Study. Diabetologia 46,674–682 (2003)
   Google Scholar
• Kantartzis K, Rittig K, Cegan A et al.: Fattyliver is independently associated with alterationsin circulating HDL2 and HDL3 subfractions.Diabetes Care 31, 366–368 (2008)
   Google Scholar
• Murao K, Wada Y, Nakamura T et al.:Effects of glucose and insulin on ratapolipoprotein A-I gene expression. J. Biol.Chem. 273, 18959–18965 (1998)
   Google Scholar
• Strauss JG, Frank S, Kratky D et al.:Adenovirus mediated rescue of lipoproteinlipase-defi cient mice: lipolysis of triglyceriderichlipoproteins is essential for HDLmaturation in mice. J. Biol. Chem. 276,36083–36090 (2001)
   Google Scholar
• Kontush A, Chapman MJ: Why is HDLfunctionally defi cient in Type 2 diabetes?Curr. Diab. Rep. 8, 51–59 (2008)
   Google Scholar
• de Souza JA, Vindis C, Hansel B et al.:Metabolic syndrome features small,apolipoprotein A-I-poor, triglyceride richHDL3 particles with defective anti-apoptoticactivity. Atherosclerosis 197, 84–94 (2008).
   Google Scholar
• Demonstrates that in metabolic syndrome,ApoA-I-poor, small, dense HDL3c exertdefective protection of endothelial cells fromoxidised LDL-(ox-LDL) induced apoptosis,potentially refl ecting functional anomaliesintimately associated with abnormal neutrallipid core content.
   Google Scholar
• Oppenheimer MJ, Sundquist K, Bierman EL:Down regulation of high-density lipoproteinreceptor in human fi broblasts by insulin andIGF-I. Diabetes 38, 117–122 (1989)
   Google Scholar
• Wang Y, Oram JF: Unsaturated fatty acidsinhibit cholesterol effl ux from macrophages byincreasing degradation of ATP-binding cassettetransporter A1. J. Biol. Chem. 277, 5692–5697(2002)
   Google Scholar
• Garvey WT, Kwon S, Zheng D et al.: Effects ofinsulin resistance and Type 2 diabetes onlipoprotein subclass particle size andconcentration determined by nuclear magneticresonance: Diabetes 52, 453– 462 (2003)
   Google Scholar
• Lund-Katz S, Laplaud S, Phillips M,Chapman MJ: Apolipoprotein B-100conformation and particle surface charge inhuman LDL subspecies: implications for LDLreceptor interaction. Biochemistry 37,12867–12874 (1998)
   Google Scholar
• Krauss RM: Lipids and lipoproteins in patientswith Type 2 diabetes. Diabetes Care27, 1496–1504 (2004)
   Google Scholar
• Gazi I, Tsimihodimos V, Filippatos T,Bairaktari E, Tselepis AD, Elisaf M:Concentration and relative distribution oflow-density lipoprotein subfractions inpatients with metabolic syndrome defi nedaccording to the National CholesterolEducation Program criteria. Metabolism 55,885–891 (2006)
   Google Scholar
• Austin MA: Genetics of low-density lipoproteinsubclasses. Curr. Opin. Lipidol. 4, 125–132(1993)
   Google Scholar
• Ordovas JM, Cupples LA, Corella D et al.:Association of cholesteryl ester transferprotein-Taq1B polymorphism with variations inlipoprotein subclasses and coronary heartdisease risk: the Framingham Study.Arterioscler. Thromb. Vasc. Biol. 20, 1323–1329(2000)
   Google Scholar
• Laakso M: Gene variants, insulin resistanceand dyslipidemia. Curr. Opin. Lipidol. 15,115–120 (2004)
   Google Scholar
• McGarry JD: What if Minkowski had beenageusic? An alternative angle on diabetes.Science 258(5083), 766–770 (1992)
   Google Scholar
• Petersen KF, Shulman GI: Etiology of insulinresistance. Am. J. Med. 119(1), S10–S16(2006)
   Google Scholar
• Unger RH: Lipotoxicity in the pathogenesis ofobesity-dependent NIDDM. Genetic andclinical implications. Diabetes 44(8), 863–870(1995)
   Google Scholar
• Lee Y, Hirose H, Ohneda M, Johnson JH,McGarry JD, Unger RH: β-cell lipotoxicity inthe pathogenesis of noninsulin-dependentdiabetes mellitus of obese rats: impairment inadipocyte-β-cell relationships. Proc. Natl Acad.Sci. USA 91(23), 10878–10882 (1994)
   Google Scholar
• Del Prato S, Enzi G, Vigili de Kreutzenberg Set al.: Insulin regulation of glucose and lipidmetabolism in massive obesity. Diabetologia.33(4), 228–236 (1990)
   Google Scholar
• Bonora E, Del Prato S, Bonadonna RC et al.:Total body fat content and fat topography areassociated differently with in vivo glucosemetabolism in nonobese and obese nondiabeticwomen. Diabetes 41(9), 1151–1159 (1992)
   Google Scholar
• Greco AV, Mingrone G, Giancaterini A et al.:Insulin resistance in morbid obesity: reversalwith intramyocellular fat depletion. Diabetes51(1), 144–151 (2002).
   Google Scholar
• Demonstrates that in morbidly obesepatients, lipid deprivation selectivelydepletes intramyocellular lipid stores andinduces a normal metabolic state (in termsof insulin-mediated whole-body glucosedisposal, intracellular insulin signaling andcirculating leptin levels) despite a persistentexcess of total body fat mass.
   Google Scholar
• Yki-Järvinen H: Fat in the liver and insulinresistance. Ann. Med. 37(5), 347–356 (2005)
   Google Scholar
• Kotronen A, Yki-Järvinen H: Fatty liver:a novel component of the metabolic syndrome.Arterioscler. Thromb. Vasc. Biol. 28, 27–38(2008)
   Google Scholar
• Sass DA, Chang P, Chopra KB: Nonalcoholicfatty liver disease: a clinical review. Dig. Dis.Sci. 50(1), 171–180 (2005)
   Google Scholar
• Agarwal N, Sharma BC: Insulin resistance andclinical aspects of nonalcoholic steatohepatitis(NASH). Hepatol. Res. 33, 92–96 (2005)
   Google Scholar
• Francis GA, Fayard E, Picard F, Auwerx J:Nuclear receptors and the control of metabolism.Annu. Rev. Physiol. 65, 261–311 (2003)
   Google Scholar
• Obici S, Feng Z, Arduini A et al.: Inhibition ofhypothalamic carnitine palmitoyltransferase-1decreases food intake and glucose production.Nat. Med. 9, 756–761 (2003)
   Google Scholar
• Morino K, Petersen KF, Shulman GI:Molecular mechanisms of insulin resistance inhumans and their potential links withmitochondrial dysfunction. Diabetes 55(2),S9–S15 (2006)
   Google Scholar
• Mootha VK, Lindgren CM, Eriksson KF et al.:PGC-1α-responsive genes involved in oxidativephosphorylation are coordinately downregulatedin human diabetes. Nat. Genet. 34,267–273 (2003)
   Google Scholar
• Patti ME, Butte AJ, Crunkhorn S et al.:Coordinated reduction of genes of oxidativemetabolism in humans with insulin resistanceand diabetes: potential role of PGC1 andNRF1. Proc. Natl Acad. Sci. USA 100(14),8466–8471 (2003)
   Google Scholar
• Maassen JA, Romijn JA, Heine RJ: Fattyacid-induced mitochondrial uncoupling inadipocytes as a key protective factor againstinsulin resistance and β-cell dysfunction:a new concept in the pathogenesis ofobesity-associated Type 2 diabetes mellitus.Diabetologia 50, 2036–2041 (2007)
   Google Scholar
• Zong H, Ren JM, Young LH et al.: AMPkinase is required for mitochondrial biogenesisin skeletal muscle in response to chronic energydeprivation. Proc. Natl Acad. Sci. USA 99(25),15983–15987 (2002)
   Google Scholar
• Wu H, Kanatous SB, Thurmond FA et al.:Regulation of mitochondrial biogenesis inskeletal muscle by CaMK. Science 296,349–352 (2002)
   Google Scholar
• Poitout V, Briaud I, Kelpe C, Hagman D:Gluco-lipotoxicity of the pancreatic β-cell.Ann. Endocrinol. 65(1), 37–41 (2004)
   Google Scholar
• Prentki M, Joly E, El-Assaad W, Roduit R:Malonyl-CoA signalling lipid partitioning andglucolipotoxicity β-cell adaptation and failurein the etiology of diabetes. Diabetes 51,S405–S413 (2002)
   Google Scholar
• Lupi R, Del Guerra S, Marselli L et al.:Rosiglitazoneprevents the impairment ofhuman islet function induced by fattyacids: evidence for a role of PPARγ2 in themodulation of insulin secretion. Am. J.Physiol. Endocrinol. Metab. 286(4), E560–E567(2004)
   Google Scholar
• Heikkinen S, Auwerx J, Argmann CA: PPARγin human and mouse physiology. Biochim.Biophys. Acta. 1771(8), 999–1013 (2007)
   Google Scholar
• Oh J, Hegele RA: HIV-associateddyslipidaemia: pathogenesis and treatment.Lancet Infect. Dis. 7, 787–796 (2007)
   Google Scholar
• Chakravarthy MV, Semenkovich CF:The ABCs of β-cell dysfunction in Type 2diabetes. Nat. Med. 13, 241–242 (2007)
   Google Scholar
• Hao M, Head WS, Gunawardana SC,Hasty AH, Piston DW: Direct effect ofcholesterol on insulin secretion: a novelmechanism for pancreatic β-cell dysfunction.Diabetes 56, 2328–2338 (2007)
   Google Scholar
• Dubé JJ, Amati F, Stefanovic-Racic M,Toledo FG, Sauers SE, Goodpaster BH:Exercise-induced alterations in intramyocellularlipids and insulin resistance: the athlete'sparadox revisited. Am. J. Physiol. Endocrinol.Metab. 294, E882–E888 (2008).
   Google Scholar
• Demonstrates a direct link betweenelevated serum cholesterol and reducedinsulin secretion, with normal secretionrestored by cholesterol depletion. Theexcess of cholesterol could inhibitsecretion by downregulation of metabolismthrough increased neuronal nitric oxidesynthase dimerization.
   Google Scholar
• Lee JS, Pinnamaneni SK, Eo SJ et al.: Saturated,but not n-6 polyunsaturated, fatty acidsinduce insulin resistance: role of intramuscularaccumulation of lipid metabolites. J. Appl.Physiol. 100, 1467–1474 (2006)
   Google Scholar
• Riccardi G, Giacco R, Rivellese AA: Dietaryfat, insulin sensitivity and the metabolicsyndrome. Clin. Nutr. 23(4), 447–456 (2004)
   Google Scholar
• Rivellese AA, Maffettone A, Iovine C et al.:Long-term effects of fi sh oil on insulinresistance and plasma lipoproteins in NIDDMpatients with hypertriglyceridemia. DiabetesCare 19(11), 1207–1213 (1996)
   Google Scholar
• Gatti E, Noe D, Pazzucconi F et al.:Differential effect of unsaturated oils and butteron blood glucose and insulin response tocarbohydrate in normal volunteers. Eur. J. Clin.Nutr. 46, 161–166 (1992)
   Google Scholar
• Bessesen DH: The role of carbohydrates ininsulin resistance. J. Nutrition 131, 2782S–2786S (2001)
   Google Scholar
• Després JP, Golay A, Sjöström L; Rimonabantin Obesity-Lipids Study Group: Effects ofrimonabant on metabolic risk factors inoverweight patients with dyslipidemia. N. Engl.J. Med. 353(20), 2121–2134 (2005)
   Google Scholar
• Stumvoll M, Häring HU, Matthaei S:Metformin. Endocr. Res. 32(1–2), 39–57(2007)
   Google Scholar
• Chavez-Tapia NC, Barrientos-Gutierrez T,Tellez-Avila FI, Sanchez-Avila F, Montano-Reyes MA, Uribe M: Insulin sensitizers intreatment of nonalcoholic fatty liver disease:Systematic review. World J. Gastroenterol.12(48), 7826–7831 (2006)
   Google Scholar
• Yki-Järvinen H: Thiazolidinediones. N. Engl.J. Med. 351(11), 1106–1118 (2004)
   Google Scholar
• Lehrke M, Lazar MA: The many faces ofPPARγ. Cell 123(6), 993–999 (2005)
   Google Scholar
• Khashab M, Chalasani N: Use of insulinsensitizers in NASH. Endocrinol. Metab. Clin.North Am. 36(4), 1067–1087 (2007)
   Google Scholar
• Belfort R, Harrison SA, Brown K et al.:A placebo-controlled trial of pioglitazone insubjects with nonalcoholic steatohepatitis.N. Engl. J. Med. 355, 2297–2307 (2006)
   Google Scholar
• Del Prato S, Bianchi C, Marchetti P: β-cellfunction and anti-diabetic pharmacotherapy.Diabetes Metab. Res. Rev. 23(7), 518–527(2007).
   Google Scholar
• In this proof-of-concept study, theadministration of pioglitazone led tometabolic and histologic improvement insubjects with nonalcoholic steatohepatitis.
   Google Scholar
• Goldberg RB, Kendall DM, Deeg MA et al.:A comparison of lipid and glycemic effects ofpioglitazone and rosiglitazone in patients withType 2 diabetes and dyslipidemia. DiabetesCare 28(7), 1547–1554 (2005)
   Google Scholar
• Chiquette E, Ramirez G, DeFronzo R:A meta-ana lysis comparing the effect ofthiazolidinediones on cardiovascular riskfactors. Arch. Intern. Med. 164, 2097–2104(2004)
   Google Scholar
• Bolen S, Feldman L, Vassy J et al.: Systematicreview: comparative effectiveness and safetyof oral medications for Type 2 diabetesmellitus. Ann. Intern. Med. 147(6), 386–399(2007)
   Google Scholar
• Tsimihodimos V, Miltiadous G,Daskalopoulou SS, Mikhailidis DP,Elisaf MS: Fenofi brate: metabolic andpleiotropic effects. Curr. Vasc. Pharmacol.1, 87–98 (2005)
   Google Scholar
• Barter PJ, Rye KA: Is there a rolefor fi brates in the management ofdyslipidemia in the metabolic syndrome?Arterioscler. Thromb. Vasc. Biol. 28, 39–46(2008)
   Google Scholar
• Avogaro A, Miola M, Favaro A et al.:Gemfi brozil improves insulin sensitivity andfl ow-mediated vasodilatation in Type 2diabetic patients. Eur. J. Clin. Invest. 31(7),603–609 (2001)
   Google Scholar
• Koh KK, Han SH, Quon MJ, Yeal Ahn J,Shin EK: Benefi cial effects of fenofi brate toimprove endothelial dysfunction and raiseadiponectin levels in patients with primaryhypertriglyceridemia. Diabetes Care 28(6),1419–1424 (2005)
   Google Scholar
• Nissen SE, Wolski K, Topol EJ: Effect ofmuraglitazar on death and major adversecardiovascular events in patients with Type 2diabetes mellitus. JAMA 294(20), 2581–2586(2005)
   Google Scholar
• Kastelein JJ: Refocusing on use ofcholesteryl ester transfer proteininhibitors. Am. J. Cardiol. 100(11), S47–S52(2007)
   Google Scholar
• Filippatos TD, Gazi IF, Liberopoulos ENet al.: The effect of orlistat and fenofi brate,alone or in combination, on small dense LDLand lipoprotein-associated phospholipase A2in obese patients with metabolic syndrome.Atherosclerosis 193, 428–437 (2007)
   Google Scholar
• Filippatos TD, Liberopoulos EN,Kostapanos M et al.: The effects of orlistatand fenofi brate, alone or in combination,on high-density lipoprotein subfractionsand pre-β1-HDL levels in obese patients withmetabolic syndrome. Diabetes Obes. Metab.10, 476–483 (2008)
   Google Scholar
• Kamanna VS, Kashyap ML: Mechanism ofaction of niacin. Am. J. Cardiol. 101(8A),20B–26B (2008)
   Google Scholar
• Paolini JF, Mitchel YB, Reyes R et al.:Effects of laropiprant on nicotinic acidinducedfl ushing in patients withdyslipidemia. Am. J. Cardiol. 101(5),625–630 (2008)
   Google Scholar
• Capuzzi DM, Morgan JM, Brusco OA Jr,Intenzo CM: Niacin dosing: relationship tobenefi ts and adverse effects. Curr. Atheroscler.Rep. 2, 64–71 (2000)
   Google Scholar
• Grundy SM, Cleeman JI, Merz CNet al.; National Heart, Lung and BloodInstitute; the American College of CardiologyFoundation and the American HeartAssociation: Implications of recent trials forthe National Cholesterol Education ProgramAdult Treatment Panel III guidelines.Circulation 110, 227–239 (2004)
   Google Scholar
• Deedwania P, Barter P, Carmena R et al.;Treating to New Targets Investigators:Reduction of low-density lipoproteincholesterol in patients with coronary heartdisease and metabolic syndrome: ana lysis ofthe Treating to New Targets study. Lancet368, 919–928 (2006)
   Google Scholar
• Stalenhoef AF, Ballantyne CM, Sarti Cet al.: A comparative study with rosuvastatinin subjects with metabolic syndrome: resultsof the COMETS study. Eur. Heart J. 26,2664–2672 (2005).
   Google Scholar
• Indicates that patients with coronary heartdisease and metabolic syndrome deriveincremental benefi t from high-doseatorvastatin therapy, irrespective of thepresence of diabetes.
   Google Scholar
• Freeman DJ, Norrie J, Sattar N et al.:Pravastatin and the development ofdiabetes mellitus: evidence for a protectivetreatment effect in the West of ScotlandCoronary Prevention Study. Circulation103, 357–362 (2001)
   Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P,Peto R; Heart Protection StudyCollaborative Group: MRC/BHF HeartProtection Study of cholesterol-loweringwith simvastatin in 5963 peoplewith diabetes: a randomisedplacebo-controlled trial. Lancet 361,2005–2016 (2003)
   Google Scholar
• Sever PS, Dahlof B, Poulter NR et al.;ASCOT investigators: Prevention ofcoronary and stroke events withatorvastatin in hypertensive patients whohave average or lower-than-averagecholesterol concentrations, in the Anglo-Scandinavian Cardiac OutcomesTrial–Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial.Lancet 361, 1149–1158 (2003)
   Google Scholar
• Jones PH: Clinical signifi cance of recentlipid trials on reducing risk in patients withType 2 diabetes mellitus. Am. J. Cardiol.99(4A), 133B–140B (2007)
   Google Scholar
• Stein EA, Lane M, Laskarzewski P:Comparison of statins inhypertriglyceridemia. Am. J. Cardiol.81(Suppl. 4A), 66B–69B (1998).
   Google Scholar